Reaction
Vasogenic Cerebral Oedema reporting signals
As of the last recalculation, Vasogenic Cerebral Oedema appears in 698 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is TEMOZOLOMIDE (PRR 74.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Temozolomide | 49 | 74.5 | 74.7 |
| Bendamustine Hydrochloride | 28 | 72.6 | 72.8 |
| Vincristine Sulfate | 40 | 43.1 | 43.2 |
| Atovaquone | 11 | 41.4 | 41.4 |
| Valganciclovir Hydrochloride Powder, | 15 | 37.5 | 37.5 |
| Bleomycin Sulfate | 12 | 35.2 | 35.3 |
| Cytarabine | 64 | 34.9 | 34.9 |
| Crizotinib | 14 | 33.5 | 33.5 |
| Brentuximab Vedotin | 10 | 29.5 | 29.5 |
| Micafungin Sodium | 7 | 24.9 | 24.9 |
| Valganciclovir | 15 | 24.2 | 24.2 |
| Valganciclovir Hydrochloride | 15 | 24.2 | 24.2 |
| Remdesivir | 10 | 22.7 | 22.7 |
| Mycophenilic Acid | 15 | 22.0 | 22.1 |
| Erlotinib | 7 | 21.8 | 21.8 |
| Doxorubicin Hydrochloride | 23 | 21.7 | 21.7 |
| Ado-Trastuzumab Emtansine | 6 | 21.4 | 21.4 |
| Phenytoin | 14 | 20.4 | 20.4 |
| Ifosfamide | 14 | 19.8 | 19.8 |
| Erlotinib Hydrochloride | 8 | 19.3 | 19.3 |
| Alteplase | 9 | 18.1 | 18.1 |
| Pertuzumab | 16 | 17.9 | 17.9 |
| Ibrutinib | 41 | 16.0 | 16.0 |
| Thiotepa | 5 | 15.7 | 15.7 |
| Doxorubicin | 44 | 15.6 | 15.7 |
| Bendamustine Hcl | 8 | 15.6 | 15.6 |
| Docetaxel Anhydrous | 31 | 14.3 | 14.3 |
| Docetaxel | 31 | 14.3 | 14.3 |
| Lapatinib | 6 | 11.6 | 11.6 |